Manni A
Department of Medicine, The Milton S. Hershey Medical Center, The Pennsylvania State University College of Medicine, Hershey 17033, USA.
Endocr Relat Cancer. 1999 Dec;6(4):483-5. doi: 10.1677/erc.0.0060483.
The estrogen dependency of human breast cancer has been successfully exploited in the treatment of early and advanced diseases and provides a unique opportunity for chemoprevention of this common malignancy. Preliminary results with the antiestrogens Tamoxifen and Raloxifene show an encouraging reduction in the incidence of breast cancer. Alternative approaches include the use of highly selective and non-toxic aromatase inhibitors and, in premenopausal women, the use of LHRH agonists in conjunction with the administration of small doses of estrogen and progesterone. The rationale for these chemopreventive strategies and their possible limitations are briefly discussed.
人类乳腺癌的雌激素依赖性已在早期和晚期疾病的治疗中得到成功应用，并为这种常见恶性肿瘤的化学预防提供了独特的机会。抗雌激素药物他莫昔芬和雷洛昔芬的初步结果显示，乳腺癌发病率令人鼓舞地降低。其他方法包括使用高选择性且无毒的芳香化酶抑制剂，对于绝经前女性，则是使用促性腺激素释放激素（LHRH）激动剂并结合小剂量雌激素和孕激素的给药。本文简要讨论了这些化学预防策略的基本原理及其可能存在的局限性。
